The neuroinvasive and neurotropic character of coronaviruses is a likely reason for neurological complications which may occur during acute COVID illness and sometimes persist or newly emerge in the post-acute phase. Terminology and temporal classification remain heterogeneous. A retrospective case series was conducted in a single center (Department of Neurology, Bielański Hospital, Warsaw, Poland). Medical records from March 2020 to December 2023 were screened. Inclusion criteria: (1) confirmed SARS-CoV-2 infection (polymerase chain reaction or antigen test and radiological findings), (2) new neurological syndrome within acute, post-acute, or post-COVID interval, and (3) diagnostic documentation. Exclusion criteria: alternative established etiology fully explaining the neurological condition. Six cases were selected for detailed analysis due to diagnostic completeness as well as etiological and temporal diversity. Cases included: (1) persistent neurocognitive and sensory symptoms (post-COVID), (2) acute ischemic stroke with internal carotid artery dissection during severe COVID-19, (3) cytotoxic lesion of the corpus callosum (CLOCC) during acute COVID-19, (4) Guillain–Barré syndrome (post-acute), (5) longitudinally extensive transverse myelitis (post-acute), and (6) delayed autoimmune cerebral vasculitis (post-COVID). Neurological presentations ranged from mild persistent symptoms to fatal outcome. Neurological complications span inflammatory, vascular, and autoimmune mechanisms across distinct temporal phases of SARS-CoV-2 infection. Precise temporal classification and systematic diagnostic protocols are essential. Prospective longitudinal studies integrating biomarkers and standardized neuroimaging are required.
Haematological inflammatory ratios, including the neutrophil-to-lymphocyte ratio (NLR), have emerged as potential biomarkers in various neurological disorders. This systematic review and meta-analysis aimed to evaluate these ratios in patients with migraine compared with healthy controls and other headache disorders, and to assess differences across migraine subtypes and clinical phases. The systematic review with meta-analysis was conducted according to the PRISMA guidelines. PubMed (MEDLINE), Web of Science, Scopus, the Cochrane Library, MEDLINE Ultimate, and Embase were searched from their inception to 26 April 2025. Additionally, backward and forward citation searches were performed. Risk of bias was assessed using the Newcastle–Ottawa Scale. Random-effects models employing the DerSimonian–Laird method and Hartung–Knapp adjustment were used to estimate pooled mean values with 95% confidence intervals. Heterogeneity was quantified with the I² and Cochran’s Q tests. Publication bias was assessed using funnel plots and Begg’s test. Twenty-three studies met the inclusion criteria, and 21 were included in the meta-analysis. The pooled mean NLR was significantly higher in patients with migraine compared to healthy controls, particularly in those with migraine with aura and during the ictal phase. No significant differences were found between migraine and tension-type headache. Other ratios showed no significant intergroup differences. Substantial heterogeneity and the observational design of included studies were noted as limitations. Among the evaluated ratios, the NLR appeared to most consistently reflect inflammatory processes in migraine, especially in migraine with aura and during the ictal period. However, its clinical utility remains uncertain and further studies are needed to clarify their potential role as diagnostic and prognostic biomarkers. PROSPERO registration: CRD420251041190. No external funding was received.